stockrowTarsus Pharmaceuticals, Inc.
TARS Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024.
- Revenue
- +63.9%
- EPS
- −4,699.1%
- Free cash flow
- −144.1%
- Total debt
- +0.90%
Quarter to September 2026, against a year earlier
Follow TARS
Alert me
Tarsus Pharmaceuticals, Inc. (TARS) Free cash flow
Tarsus Pharmaceuticals, Inc.'s free cash flow for fiscal 2025 was −$22.3M, compared with −$89.6M in fiscal 2024. Over the twelve months to 30 September 2026 it was $32.4M. Over the past ten years it has ranged from −$123.0M (fiscal 2023) to $3.2M (fiscal 2021); the current reading is higher than 50% of that period. Tarsus Pharmaceuticals, Inc. ranks 39th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$22.3M | — |
| FY2024 | −$89.6M | — |
| FY2023 | −$123.0M | — |
| FY2022 | −$49.5M | — |
| FY2021 | $3.2M | — |
| FY2020 | −$21.6M | — |
| FY2019 | −$3.8M | — |
| FY2018 | −$1.2M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | −$7.2M | — |
| Jun 2026 | $57.2M | — |
| Mar 2026 | −$30.5M | — |
| Dec 2025 | $13.0M | (20.65%) |
| 25 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $82.0M |
| TARS Tarsus Pharmaceuticals, Inc. | $32.4M |
| TLX Telix Pharmaceuticals Limited compare | −$4.4M |
| ELVN Enliven Therapeutics, Inc. compare | −$67.0M |
| CELC Celcuity, Inc. compare | −$192.3M |
| VRDN Viridian Therapeutics, Inc. compare | −$343.4M |
| DNLI Denali Therapeutics Inc. compare | −$450.0M |
| VKTX Viking Therapeutics, Inc. compare | −$462.6M |
| DYN Dyne Therapeutics, Inc. compare | −$480.4M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on TARS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement